Sepsis Clinical Trial
Official title:
Activity and Expression of Plasma Arginase in Patients With Severe Sepsis or Septic Shock as Prognostic Value
Sepsis is an acute pathology defined as an inappropriate response of the host to infection,
resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis
associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring
vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma
L-arginine deficiency. This deficiency induces a lower availability of L-arginine for
multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in
the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a
lower synthesis induces a vascular and endothelial dysfunction that can promote the
occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in
patients with sepsis and appears correlated with severity.
L-arginine deficiency can have multiple origins:
- L-arginine deficiency resulting from a decrease in endogenous production from citrulline
synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in
patients with sepsis and is characterized biologically by elevated plasma levels of
I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis
marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity).
- L-arginine deficiency may also result from a catabolism increase via arginase activity
increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the
synthesis of urea and ornithine from L-arginine. An increase in arginase activity would
decrease the available reserves of L-arginine for NO synthesis.
The objectives of this work is to evaluate, in patients with severe sepsis or septic shock,
the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms
Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and
enterocyte dysfunction.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
| Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
| Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A |